Dow Inc. heads into the back half of May with shorts rebuilding sharply and options traders tilting more defensive, even as a fresh analyst upgrade and a clutch of post-earnings target raises pull the Street in the other direction.
Short interest has become the week's most telling data point. Estimated shorts jumped roughly 18% in a single week to 3.5% of the free float — a sharp reversal from a period of relative calm through April and early May. The raw share count climbed from around 20.7 million to 25.1 million between May 8 and May 12, the biggest single-week increase in the 30-day window. That is still a moderate absolute level, but the velocity of the move is notable. Borrow costs remain cheap at 0.36% APR, and availability is loose — very few of the shares in the lending pool have been taken, well below this name's 52-week peak utilization of 15.8% — so this is genuine short conviction being expressed, not a squeeze-driven technical. The borrow market is not at all strained.
Options positioning corroborates the cautious lean. The put/call ratio has crept up to 0.99, about 1.4 standard deviations above its 20-day average of 0.94 — not extreme, but the steady drift higher in the PCR through late April and into May tells a consistent story of rising demand for downside cover. The 52-week high on the PCR is 1.06, so the current reading is closing in on the upper end of the past year's range. Neither the short interest nor the options picture is screaming extreme crowding, but both are pointing in the same cautious direction.
The analyst community is more divided. Argus Research upgraded DOW to Buy from Hold this week — the most recent move in the coverage. Post-April-earnings activity showed a similar split: RBC Capital lifted its Outperform target to $51, JP Morgan raised its Overweight target to $42, and BMO bumped to $46 — all positive adjustments after the Q1 print. But UBS kept a Neutral rating and trimmed its target to $39, essentially matching the current price of $39.43 and implying no upside, while Bank of America maintained an Underperform with a $35 target. The consensus sits at "hold" with five buys against nine holds, a setup that reflects genuine uncertainty rather than broad conviction. EV/EBITDA is running near 7x and the P/E near 15x — not stretched, but the bear case is clear: margin compression in polyethylene, elevated energy costs, and tariff headwinds are all live concerns, and the bull case rests heavily on volume recovery and anti-dumping tailwinds that have yet to fully materialise.
On the peer front, the week's weakness was broad across commodity chemicals. Closest peer LYB fell 4.4% on the week while CE dropped 13.8% and ASIX lost 14%. DOW's 3.4% weekly decline looks measured by comparison. That relative resilience may partly reflect the April earnings reaction — the stock slipped just 0.4% the day after its Q1 print before recovering 4.3% over the following five days — suggesting the market found the quarterly numbers acceptable even if not impressive. The next earnings event is scheduled for July 23.
The numbers to watch heading into June are whether the short rebuild continues at this pace and whether the options PCR pushes through its 52-week high near 1.06 — together those would signal that positioning is genuinely turning, rather than just reflecting a single week's repositioning.
See the live data behind this article on ORTEX.
Open DOW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
